Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia
The US Food and Drug Administration (FDA) has approved use of recombinant human interleukin 11 (rhIL-11; oprelvekin; Neumega - Genetics Institute) to increase platelet counts and decrease the need for platelet transfusions in patients with severe thrombocytopenia caused by chemotherapy for nonmyeloid malignancies....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1032
Article Code: 1032b
Date: July 31, 1998
Volume: 40
Pages: 75-77
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1032
Article Code: 1032b
Date: July 31, 1998
Volume: 40
Pages: 75-77
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)